The Recall Desk
ModerateFDA (Drugs)·D-842-2013·Announced 2013-08-14

Teva Recalls Terazosin Hydrochloride Capsules Due to Labeling Error

Teva Pharmaceuticals is recalling 6,267 bottles of Terazosin Hydrochloride capsules because the 10 mg label contained 5 mg capsules.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class II, and the hazard is a labeling error regarding drug strength. This aligns with the rubric for minor labeling errors or low-risk contamination.

Plain-English summary

Teva Pharmaceuticals USA, Inc. is recalling 6,267 bottles of Terazosin Hydrochloride Capsules, 10 mg, 100-count, Rx only. The product is identified by NDC 0093-4339-01, Lot # N07321, and an expiration date of 6/14.

The recall was initiated due to a labeling error where unopened, sealed bottles labeled as containing 10 mg capsules actually contained 5 mg capsules. This discrepancy could result in patients receiving a lower dose than prescribed.

The affected product was distributed nationwide and in Puerto Rico. Consumers and healthcare providers should check their inventory for the specific lot number and expiration date listed above. If found, the product should be returned to the pharmacy or point of purchase for a refund or replacement.

The recalled product

Product
Terazosin Hydrochloride Capsules,10 mg, 100-count bottle, Rx only, Manufactured for Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0093-4339-01
Affected units
6,267

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot # N07321
  • Exp 6/14

Distribution

Distributed nationwide across the United States.

The notice also names 1 state specifically: